Educational Objectives

 Discuss the genetics of low HDL.

 Explain the mechanisms of HDL metabolism.

 Discuss clinical trial data in patients with low HDL-C,
 and combination therapy studies with niacin, including AFCAPS,
 VA-HIT and HATS/FATS.

 Select appropriate management for patients with dyslipidemia,
 with low HDL, e.g., niacin, fibrates, statins, etc.

Subject Content

 HDL metabolism.

 Pharmacokinetics of lipids including HDL.

 Safety issues and efficacy of extended-release niacin, other niacin
 formulations, fibrates, and statins in the management of low HDL.

 Clinical trials of extended-release niacin in patients with dyslipidemia.

This edition is for information and study purposes only as the
CME credits have expired.

Back to Complex Lipid Management